文献速递新生儿儿童感染儿童消化与营养

血浆miR-1290是早期诊断坏死性小肠结肠炎的新型特异性生物标志物

Plasma miR-1290 Is a Novel and Specific Biomarker for Early Diagnosis of Necrotizing Enterocolitis-Biomarker Discovery with Prospective Cohort Evaluation.
PubMed 文献 · J Pediatr · 2018-10-24

该研究通过微阵列分析、病例对照研究和前瞻性队列研究(n=301)发现,血浆miR-1290(第0天>220拷贝/µL)对轻度内科和重度外科坏死性小肠结肠炎(NEC)均有最佳诊断价值。对中间水平(220-650拷贝/µL)者,两阶段算法加入C反应蛋白(第1天>15.8 mg/L)后灵敏度0.83、特异度0.96、阳性预测值0.75、阴性预测值0.98。36例NEC患儿中7例(19.4%)可提前7.8-32.2小时(中位13.3小时)诊断。

要点

  • 血浆miR-1290>220拷贝/µL对NEC具有最佳诊断价值。
  • 中间水平者联合CRP>15.8 mg/L可优化诊断效能。
  • miR-1290可使部分NEC患儿提前中位13.3小时诊断。

核心结论

  • 血浆miR-1290是新型特异性生物标志物,可有效区分NEC与新生儿败血症。
  • miR-1290有助于新生儿科医生及时决策,将社区医院的NEC患儿转至三级外科中心。

研究设计与样本

  • 研究分3个阶段:微阵列分析比较NEC与败血症及非NEC/非败血症病例的血浆miRNA表达谱。
  • 病例对照研究定量失调miRNA作为NEC潜在特异性生物标志物。
  • 前瞻性队列研究(n=301)评估最佳miRNA生物标志物的诊断价值。

主要发现

  • NEC组与败血症组及非NEC/非败血症组相比呈现独特的miRNA表达谱。
  • 病例对照研究识别出miR-1290、miR-1246和miR-375为NEC特异性生物标志物。
  • 队列研究中,血浆miR-1290(第0天;>220拷贝/µL)对轻度内科和重度外科NEC病例均提供最大诊断价值。
  • 20例miR-1290>650拷贝/µL的婴儿中,15例诊断为NEC。
  • 36例NEC婴儿中7例(19.4%)使用miR-1290可提前7.8-32.2小时(中位13.3小时)诊断。

关键数值与推荐

  • 血浆miR-1290第0天>220拷贝/µL为诊断NEC的阈值。
  • 对miR-1290中间水平(220-650拷贝/µL)者,两阶段算法加入C反应蛋白(第1天>15.8 mg/L)。
  • 两阶段算法诊断效能:灵敏度0.83、特异度0.96、阳性预测值0.75、阴性预测值0.98。

临床怎么用

  • 血浆miR-1290可用于早期区分NEC与新生儿败血症。
  • 对miR-1290中间水平者,可结合第1天CRP>15.8 mg/L进行两阶段评估。
  • miR-1290有助于及时决策将社区医院NEC患儿转至三级外科中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To discover specific circulating microRNA (miRNA) biomarkers for the early differentiation of necrotizing enterocolitis (NEC) from neonatal sepsis and inflammatory conditions. STUDY DESIGN: The study comprised 3 distinct phases: differential microarray analysis to compare plasma miRNA expression profiles of NEC vs sepsis and non-NEC/nonsepsis cases, a case-control study to quantify dysregulated miRNAs as potential specific biomarkers of NEC, and a prospective cohort study to assess the diagnostic usefulness of the best miRNA biomarker(s). RESULTS: A distinct miRNA expression profile was observed in the NEC compared with the sepsis and non-NEC/nonsepsis groups. miR-1290, miR-1246, and miR-375 were discovered to be specific biomarkers of NEC in the case-control study. In the cohort study (n = 301), plasma miR-1290 (day 0; >220 copies/µL) provided the greatest diagnostic usefulness for identifying both mild medical and severe surgical NEC cases. Of 20 infants with miR-1290 >650 copies/µL, 15 were diagnosed with NEC. Incorporating C-reactive protein (day 1; >15.8 mg/L) for cases with intermediate levels (220-650 copies/µL) in a 2-stage algorithm further optimized the diagnostic profile with a sensitivity of 0.83, a specificity of 0.96, a positive predictive value of 0.75, and a negative predictive value of 0.98. Importantly, 7 of 36 infants with NEC (19.4%) could be diagnosed 7.8-32.2 hours earlier (median, 13.3 hours) using miR-1290. CONCLUSIONS: Plasma miR-1290 is a novel and specific biomarker that can effectively differentiate NEC cases from neonatal sepsis. miR-1290 facilitates neonatologists to confidently and timely reach a decision for early transfer of sick infants with NEC from community-based hospitals to tertiary surgical centers.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Ng PC, Chan KYY, Yuen TP, et al. Plasma miR-1290 Is a Novel and Specific Biomarker for Early Diagnosis of Necrotizing Enterocolitis-Biomarker Discovery with Prospective Cohort Evaluation. J Pediatr. 2018. PMID: 30529132. doi:10.1016/j.jpeds.2018.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。